title: Long-term risperidone treatment induces visceral adiposity associated with hepatic steatosis in mice: a magnetic resonance approach.
abstract: Although atypical antipsychotic drugs (APDs) have led to significant advances in the treatment of psychotic disorders, they still induce metabolic disturbances. We aimed at characterizing the metabolic consequences of a risperidone treatment and at establishing a link with noninvasive MR markers, in order to develop a tool for predicting symptoms of the metabolic syndrome. Fat deposition and liver morphometry were assessed by T1-weighted imaging. Fatty acid composition and fat accumulations in tissues were determined using MR spectroscopy with and without water suppression, respectively. Risperidone treatment induced a weight gain accompanied with metabolic disturbances such as hyperglycemic status, an increase in visceral adipose tissue (VAT), and liver fat depositions. Correlations using Methylene-Water Ratio (MWR) and Polyunsaturated Index (PUI) demonstrated a concomitant increase in the weight gain, VAT and liver fat depositions, and a decrease in the quantity of polyunsaturated fatty acids. These results were consistent with a hepatic steatosis state. We evaluated the ability of MR techniques to detect subtle metabolic disorders induced by APDs. Thus, our model and methodology offer the possibility to investigate APDs side effects in order to improve the health conditions of schizophrenic patients.
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; Département de Pharmacologie Médicale, CHULille, EA 1046, 59000 Lille, France ; Inserm, U837, 59000 Lille, France ; IMPRT-IFR114, 59000 Lille, France.
authors.forename: Florent
authors.initials: F
authors.lastname: Auger
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; Département de Pharmacologie Médicale, CHULille, EA 1046, 59000 Lille, France ; IMPRT-IFR114, 59000 Lille, France ; Faculté de Pharmacie, 59006 Lille, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Duriez
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; Faculté de Pharmacie, 59006 Lille, France ; Inserm, U1011, 59000 Lille, France ; Institut Pasteur de Lille, 59019 Lille, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Martin-Nizard
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; IMPRT-IFR114, 59000 Lille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Durieux
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; Département de Pharmacologie Médicale, CHULille, EA 1046, 59000 Lille, France ; IMPRT-IFR114, 59000 Lille, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Bordet
authors.affiliation: Université Lille Nord de France, 59000 Lille, France ; IMPRT-IFR114, 59000 Lille, France ; UArtois, 62300 Lens, France ; Laboratoire de Pharmacologie Médicale, EA 1046, Faculté de Médecine, Université Lille2, Pôle Recherche, 1 Place de Verdun, 59045 Lille Cedex, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Pétrault